Disc Medicine, Inc. is a high-risk pharmaceutical company based in the United States of America, with a focus on transforming the lives of patients with hematologic disorders. Specializing in ESG-driven therapeutic candidates that target red blood cell biology, Disc Medicine is committed to providing hope and empowerment to patients suffering from hematologic diseases. Their portfolio includes innovative treatments that modify biological pathways related to red blood cell formation and heme biosynthesis, aiming to make a positive impact on patient health.